Certified by Founder Lodge
EpiBiologics
United States - San Mateo, California
START UP
1 Disclosed Funding Rounds $107,000,000
0 Participating Investments
-
Founded date
2022
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrad
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| January, 09 ,2026 | Series B | $107,000,000 |
Johnson & Johnson
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
